Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is MedAssets the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if MedAssets (Nasdaq: MDAS  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at MedAssets.


What We Want to See


Pass or Fail?

Growth 5-Year Annual Revenue Growth > 15% 31.4% Pass
  1-Year Revenue Growth > 12% 39.5% Pass
Margins Gross Margin > 35% 79.5% Pass
  Net Margin > 15% 0.1% Fail
Balance Sheet Debt to Equity < 50% 229.6% Fail
  Current Ratio > 1.3 0.75 Fail
Opportunities Return on Equity > 15% 0.1% Fail
Valuation Normalized P/E < 20 NM NM
Dividends Current Yield > 2% 0% Fail
  5-Year Dividend Growth > 10% 0% Fail
  Total Score   3 out of 9

Source: S&P Capital IQ. NM = not meaningful due to insignificant net income. Total score = number of passes.

With only three points, MedAssets isn't running as smoothly as it could be. But the company is in a hot area of the health-care industry and has plenty of growth potential for the future.

MedAssets is helping to bring technology to the medical industry, with its health-care information services for hospitals and other health-care providers. With rising health-care costs and reform focused on maximizing efficiency in the industry, IT solutions have played an increasing role in trying to restructure and streamline hospital operations.

MedAssets is far from the only company trying to make health-care facilities run smoother. But competitors Cerner (Nasdaq: CERN  ) , Quality Systems (Nasdaq: QSII  ) , and Computer Programs & Systems (Nasdaq: CPSI  ) all have businesses that involve putting health records into electronic form. By contrast, MedAssets focuses largely on internal finance areas like supply chain analysis and cost management as well as reimbursement tracking. That differentiation has allowed MedAssets to do well at times when other health IT companies fell flat, but its specialization helps distinguish MedAssets from Accenture (NYSE: ACN  ) and other big consultants that dabble in the industry.

Back in February, shares of MedAssets soared on rumors that the company had hired a Wall Street firm to look into doing a leveraged buyout. So far, though, those rumors haven't amounted to action, but the company keeps producing strong results -- and raised its full-year guidance last week.

For MedAssets to keep improving, it needs to translate its growth into bigger profits. Once it does that, it can go to work at boosting its balance sheet and moving closer to perfection in the years to come.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

MedAssets may not be the perfect stock, but we've got some ideas you may like better. Let me invite you to learn about three smart long-term stock plays in the Fool's latest special report. It's yours for the taking and is absolutely free, but don't miss out -- click here and read it today.

Click here to add MedAssets to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Accenture and Quality Systems. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1880704, ~/Articles/ArticleHandler.aspx, 5/24/2016 8:26:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 11 hours ago Sponsored by:
DOW 17,492.93 -8.01 -0.05%
S&P 500 2,048.04 -4.28 -0.21%
NASD 4,765.78 -3.78 -0.08%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
MDAS $0.00 Down +0.00 +0.00%
MedAssets CAPS Rating: **
ACN $116.18 Down -0.29 -0.25%
Accenture CAPS Rating: ****
CERN $54.14 Down -0.42 -0.77%
Cerner CAPS Rating: ****
CPSI $42.64 Up +1.46 +3.55%
Computer Programs… CAPS Rating: *****
QSII $12.91 Down -0.38 -2.86%
Quality Systems CAPS Rating: ****